Crossmark

Everolimus-eluting bioresorbable scaffolds for treatment of coronary artery disease in patients with diabetes mellitus: the midterm follow-up of the prospective ABSORB DM Benelux study

Crossref DOI link: https://doi.org/10.1186/s12933-019-0827-z

Published Online: 2019-03-09

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hommels, T. M.

Hermanides, R. S.

Rasoul, S.

Berta, B.

IJsselmuiden, A. J. J.

Jessurun, G. A. J.

Benit, E.

Pereira, B.

De Luca, G.

Kedhi, E.
Clinical Trials ^BETA

Clinical trials referenced in this document:

ntr5447 at Netherlands National Trial Register

Documents that mention this clinical trial

Everolimus-eluting bioresorbable scaffolds for treatment of coronary artery disease in patients with diabetes mellitus: the midterm follow-up of the prospective ABSORB DM Benelux study
https://doi.org/10.1186/s12933-019-0827-z
Funding

Funding for this research was provided by:

Maatschap Cardiologie Isala Hartcentrum, Isala Klinieken, Zwolle
License Information

Text and Data Mining valid from 2019-03-09

Version of Record valid from 2019-03-09
More Information

Article History

Received: 3 January 2019

Accepted: 18 February 2019

First Online: 9 March 2019

Document is current

Any future updates will be listed below